CARTITUDE-1 5-Year Follow-Up Analysis
5-Year Baseline Characteristics
5-year follow-up
CARTITUDE-1 study1
You are now viewing an analysis from the CARTITUDE-1 trial with a median duration of follow-up of 61.3 months.
This information is not included in the current USPI. The clinical significance is unknown.
This information is not included in the current USPI. The clinical significance is unknown.
This post hoc analysis was conducted ≥5 years (61.3-month median follow-up) after infusion to provide further insights into long-term clinical benefits associated with CARVYKTI®.
Baseline characteristics:
All Infused Patients (N=97)
97% daratumumab-refractory
(n=94/97)
25.3% with high-risk* cytogenetics
(n=23/91)
13.4% with extramedullary plasmacytomas
(n=13/97)
87.6% triple-class refractory (n=85/97)
≥5 Years Alive and Progression-Free (n=32)
PD Within 5 Years (n=46)
Previous LoT, median (range)
6.5 (3-14)
5.0 (3-18)
High-risk* cytogenetics, No./n (%)
7/30 (23.3)†
12/45 (26.7)
Extramedullary plasmacytomas, No. (%)
4 (12.5)‡
6 (13.0)
≥5 Years Alive and
Progression-Free (N=32)
Progression-Free (N=32)
Previous LoT, median (range)
6.5 (3-14)
High-risk* cytogenetics,
No./n (%)
No./n (%)
7/30 (23.3)†
Extramedullary plasmacytomas,
No. (%)
No. (%)
4 (12.5)‡
PD Within 5 Years (N=46)
Previous LoT, median (range)
5.0 (3-18)
High-risk* cytogenetics,
No./n (%)
No./n (%)
12/45 (26.7)
Extramedullary plasmacytomas,
No. (%)
No. (%)
6 (13.0)
del=deletion; LoT=line(s) of therapy; PD=progressive disease; t=translocation; USPI=US Prescribing Information.
*Either del(17p), t(14;16), or t(4;14).
†4 patients had del(17p), 2 had t(14;16), and 1 had del(17p) and t(14;16).
‡Extramedullary disease denotes soft tissue plasmacytoma not contiguous with bone.
You are now viewing an analysis from the CARTITUDE-1 trial with a median duration of follow-up of 61.3 months.
This information is not included in the current USPI and should be interpreted with caution.
This information is not included in the current USPI and should be interpreted with caution.
36% of responders
continued to respond at 60 months1,2
Duration of response in CARVYKTI®
responders (n=94)1,2*†
• At data cutoff (median follow-up of 61.3 months), 46% of patients (45/97) were alive and in long-term follow-up
Percentages rounded to nearest whole number.
CI=confidence interval; DOR=duration of response; USPI=US Prescribing Information.
*Responders defined as having partial response or better as determined by investigator.3
†Median follow-up was 61.3 months in the All Treated Analysis Set. Response and disease progression assessed by investigator.
Learn more about CARVYKTI®